Hepatitis B Surface Antigen (HBsAg), ayw, Recombinant

Catalog No : USB-H1909-18E
1127.62€
0.00€

Shipping cost plus VAT not included , delivery in 7-14 business days

Product name Hepatitis B Surface Antigen (HBsAg), ayw, Recombinant
Catalog No USB-H1909-18E
Supplier’s Catalog No H1909-18E
Supplier US Biologicals
Source antigen Hepatitis B Virus, recombinant protein expressed by Pichia pastoris
Reactivity
Cross reactivity
Applications
Molecular weight 25.5
Storage -70°C
Other names
Grade Highly Purified
Purity ~95% (SDS-PAGE). Purification is conducted from broken yeast cells by the following scheme: clarification, microfiltration, ultrafiltration, adsorption chromatography, ion-exchange chromatography, ultracentrifugation and sterile filtration.
Form Supplied as a liquid in PBS, pH 7.2, 0.001% Thimerosal.
Reactivity life 6 months
Note For reserch purpose only
Purity ~95% (SDS-PAGE). Purification is conducted from broken yeast cells by the following scheme: clarification, microfiltration, ultrafiltration, adsorption chromatography, ion-exchange chromatography, ultracentrifugation and sterile filtration.
Description Recombinant Hepatitis B Surface Antigen (adw) contains full-length HBsAg (226aa, molecular weight of 25.5kD). Hepatitis B is an infection of the liver caused by the hepatitis B virus. Approximately 5-10% of adults and 90% of babies who are infected with HBV will go on to carry the virus for the rest of their lives. These people will pass the virus onto others. HBV is excreted in body fluids such as semen, saliva, blood and urine in persons with acute or chronic infection. The route of transmission can include homosexual or heterosexual activity, blood-borne exposure (needles, transfusion), mother-infant, close personal contact and even by consuming contaminated food or water. Thus, Hepatitis B has become a major public health concern. When HBV invades the body it causes liver damage through induction of auto-immunity. Liver cell injury results from cytotoxic T cell activity rather than viral cytotoxic activity. The principal screening test for detecting current (acute or chronic) HBV infection is the identification of HBsAg, an envelope lipoprotein. This is the first immunological marker to appear in a patient’s serum and exist in high quantities in the blood. Patients who are HBsAg positive develop chronic persistent hepatitis (CPH) and chronic active hepatitis (CAH). Patients with CPH usually remain in good health. Those with CAH have progressive liver damage with the outcome being portal fibrosis, cirrhosis, or hepatocellular carcinoma. Screening for HBsAg is recommended for all donors, pregnant women and those individuals who at high risk. Presence of this marker is conclusive proof of HBV infection. This immunoassay measures HBsAg through antigen-antibody interactions. Amino Acid Sequence: MENITSGFLG PLLVLQAGFF LLTRILTIPQ SLDSWWTSLN FLGGSPVCLG QNSQSPTSNH SPTSCPPICP GYRWMCLRRF IIFLFILLLC LIFLLVLLDC QGMLPVCPLI PGSTTTSTGP CRTCTTPAQG NSMFPSCCCT KPTDGNCTCI PIPSSWAFAK YLWEWASVRF SWLSLLVPFV QWFVGLSPTV WLSVIWMMWY  WGPSLYNILS PFIPLLPIFF CLWVYI                                        Applications: Suitable for use in ELISA, Western Blot. Other applications not tested. Recommended Dilution: ELISA: Suitable for use as solid-phase coating antigen. Optimal dilutions to be determined by the researcher. Storage and Stability: May be stored at 4°C for short-term only. For long-term storage, aliquot to avoid repeated freezing and thawing and freeze at -70°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Aliquots are stable for at least 12 months. Also Available: H1909-17: Hepatitis B Surface Antigen adr, Recombinant (HBsAg adr) H1909-18: Hepatitis B Surface Antigen adw, Recombinant (HBsAg adw) H1909-22: Hepatitis B Surface Antigen ayw, Recombinant (HBsAg ayw)